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RESUMEN 
Lunasin es un péptido quimiopreventivo de 43-amino ácidos que existe 
naturalmente con propiedades anticancerígenas y antiinflamatorias demostradas.  
Los objetivos de este estudio fueron determinar el efecto de la temperatura en la 
estructura secundaria de lunasin, desarrollar un método para aislar lunasin del 
plasma humano utilizando una columna microgiratoria de intercambio iónico y 
cuantificar la cantidad de lunasin utilizando ensayo por inmunoabsorción ligado a 
enzimas optimizado (ELISA por sus siglas en inglés).  Lunasin fue purificada 
utilizando una combinacón de cromatografía por intercambio iónico, ultrafiltración 
y cromatografía por filtración en gel.  Dicroismo circular demostró que el 
incremento de temperatura de 25 a 100 °C resultó en cambios en la estructura 
secundaria de lunasin y en su capacidad para interactuar con anticuerpos 
policlonales de conejo.ELISA demostró que anticuerpos policlonales de conejo 
para lunasin tienen una titulación de 250 y una actividad específica de 0.05 
ml/µg.Se detectó una respuesta linear entre 16 a 48 ng de lunasin por mL (y = 
0.03x – 0.38, R2 = 0.96).  El uso de la columna microgiratoria de dietilaminoetil 
(DEAE) para aislar el plasma con lunasin agregada demostró que la mayor 
cantidad de lunasin (37.8-46.5%) se unió a la columna eluida con el amortiguador 
Tris-HCl, pH 7.5 con un rendimiento de hasta 76.6%.  En conclusión, lunasin 
puede ser aislada del plasma humano con una técnica simple utilizando una 
columna microgiratoria de DEAE y puede ser cuantificada utilizando un 
procedimiento validado de inmunoensayo optimizado.  Este método puede ser 
usado directamente para cuantificar lunasin en plasma en diferentes estudios 
humanos y animales apuntando a determinar su biodisponibilidad. 
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ABSTRACT 
Lunasin is a 43-amino acid naturally occurring chemopreventive peptide 
with demonstrated anti-cancer and anti-inflammatory properties. The objectives of 
this study were to determine the effect of temperature on the secondary structure 
of lunasin, to develop a method of isolating lunasin from human plasma using an 
ion-exchange microspin column and to quantify the amount of lunasin using an 
optimized enzyme-linked immunosorbent assay. Lunasin was purified using a 
combination of ion-exchange chromatography, ultrafiltration and gel filtration 
chromatography. Circular dichroism showed that increased in temperature from 25 
to 100 °C resulted in changes on the secondary structure of lunasin and its 
capability to interact with rabbit polyclonal antibody. Enzyme linked 
immunosorbent assay showed that lunasin rabbit polyclonal antibody has a titer of 
250 and a specific activity of 0.05 mL/μg. A linear response was detected between 
16 to48 ng lunasin per mL (y = 0.03x 0.38, R2 = 0.96). The use of 
diethylaminoethyl microspin column to isolate spiked lunasin in human plasma 
showed that most lunasin (37.8–46.5%) bound to the column eluted with Tris–HCl 
buffer, pH 7.5 with a yield up to 76.6%. In conclusion, lunasin can be isolated from 
human plasma by a simple DEAE microspin column technique and can be 
quantified using a validated and optimized immunoassay procedure. This method 
can be used directly to quantify lunasin from plasma in different human and animal 
studies aiming to determine its bioavailability.  
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INTRODUCTION 
Lunasin is a 43-amino acid naturally occurring peptide with demonstrated 
chemopreventive and therapeutic properties (Dia & Gonzalez de Mejia, 2011; 
Galvez, Chen, Macasieb, & de Lumen, 2001). It was originally isolated in soybean 
(Galvez & de Lumen, 1999) and has been found in other plant species including 
amaranth (Maldonado-Cervantes et al., 2011; Silva-Sanchez et al., 2008), 
Solanum (Jeong, Jeong, Kim et al., 2007, Jeong, Jeong, Park et al., 2007), barley 
(Jeong, Lam, & de Lumen, 2002), and wheat (Jeong, Jeong, Kim et al., 2007, 
Jeong, Jeong, Park et al., 2007). Its biological properties are attributed to the 
presence of a cell adhesion motif composed of arginine, glycine and aspartic acid 
residues as well as to the nine aspartic acid residues located on its carboxylic acid 
end. The reported chemopreventive properties of lunasin included prevention of 
chemically-induced carcinogens (Hsieh, Hernandez-Ledesma, & de Lumen, 2011), 
inhibition of lipopolysaccharide-induced inflammation in macrophages (de Mejia & 
Dia, 2009; Dia, Wang, Oh, de Lumen, & de Mejia, 2009a; Hernandez- Ledesma, 
Hsieh, & de Lumen, 2009a, 2009b; Liu & Pan, 2010) as well as induction of 
apoptosis in different human cancer cell lines (de Mejia, Wang, & Dia, 2010; Dia & 
de Mejia, 2010; Hsieh, Hernandez-Ledesma, & de Lumen, 2010b). Animal models 
also showed the capability of lunasin to prevent or inhibit the process of 
carcinogenesis such as prevention of mammary carcinogenesis in a xenograft 
model of breast cancer (Hsieh, Hernandez-Ledesma, & de Lumen, 2010a), 
prevention of chemically-induced breast carcinogenesis (Hsieh, Hernandez-
Ledesma, & de Lumen, 2010c) and inhibition of colon cancer metastasis and 
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potentiation of the chemotherapeutic effect of oxaliplatin in an experimental model 
of colon cancer metastasis (Dia & Gonzalez de Mejia, 2011).  
One of the most important characteristics of any dietary compound with 
demonstrated biological properties is its capability to remain intact and bioactive 
after absorption, distribution and metabolism termed as bioavailability. 
Bioavailability refers to the fraction of the ingested compound that reaches 
circulation. In our previous study in human fed with 50 g of soy protein for 5 days, 
lunasin was found in plasma after 30 min and 1 h of soy protein ingestion (Dia, 
Torres, de Lumen, Erdman, & de Mejia, 2009b). Another study also demonstrated 
the bioavailability of soy lunasin in an animal model and was found in a variety of 
organs and tissues including blood, urine, brain, colon and feces (Hsieh et al., 
2010c). Moreover, lunasin from different sources such as barley, rye and wheat 
was also reported to be bioavailable (Jeong, Jeong, Hsieh, Hernandez-Ledesma, 
& de Lumen, 2010; Jeong, Jeong, Kim et al., 2007, Jeong, Jeong, Park et al., 
2007; Jeong et al., 2009). The method used in these studies were either an 
expensive kit or isotopic-labelling of the molecule prior to feeding and 
quantification of the labelled element after animal euthanasia making the process 
of measuring bioavailability time-consuming and costly.  
The objectives of this study were to determine the effect of temperature on 
structure–activity of lunasin as well as to develop a method of isolating lunasin in 
human plasma using an ion-exchange microspin column and to quantify the 
amount of lunasin using an optimized enzyme-linked immunosorbent assay 
(ELISA). We report here the effect of temperature on the structure–activity 
property of lunasin purified from defatted soybean flour. Also, we show that lunasin 
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spiked in human plasma can be isolated and quantified using diethylaminoethyl 
(DEAE) anion exchange chromatography and an optimized ELISA protocol.  
13 
 
MATERIALS AND METHODS 
Materials 
Microspin columns and DEAE resin were purchased from GE Healthcare 
Life Sciences (Piscataway, NJ, USA). Lunasin rabbit polyclonal antibody was a 
kind gift from Dr. Ben O. de Lumen, University of California at Berkeley. All other 
chemicals were purchased from Sigma–Aldrich unless otherwise stated.  
Purification of lunasin from deffated soybean flour 
Lunasin from defatted soybean [Glycine max (L.) Merill] flour was purified 
using a previously reported protocol with modifications (Dia et al., 2009a). Briefly, 
200 g of defatted soybean flour obtained from National Soybean Research 
Laboratory, University of Illinois Urbana-Champaign was resuspended in 1-L of 
deionized water and mixed overnight at 4 °C. The suspension was centrifuged 
12,000g for 10 min, supernatant was pooled and filtered. Two-hundred and fifty 
millilitres of supernatant was loaded in pre-equilibrated XK 50/30 column packed 
with DEAE anion exchange resin. Separation was carried out using 20 mM Tris–
HCl pH 7.5 (buffer A) and buffer B containing 2 M NaCl pH 7.5. Bound protein was 
eluted with increasing concentration of buffer B in a step gradient mode from 5% 
(25 min), 10% (75 min), 20% (100 min) and 100% (25 min) at a flow rate of 10 
mL/min. Fractions containing high concentration of lunasin were desalted using an 
Amicon ultrafiltration vessel with YM-1000 membrane (Millipore, molecular weight 
cut-off of 1 kDa) under 20 psi helium gas until the volume of the retentate was 
approximately 10% of the original volume. Fifteen millilitre of the retentate was 
then loaded on a Superdex 75 Prep Grade size exclusion XK 26/70 pre-
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equilibrated with 20 mM Tris– HCl containing 0.15 M NaCl pH 7.5. Proteins were 
eluted with 20 mM Tris–HCl containing 0.15 M NaCl, pH 7.5, at a flow rate of 4 
mL/min and fractions were collected every minute for 30 min after one void 
volume. Fractions with high concentrations of lunasin were pooled, concentrated 
and further purified. Five hundred microlitres of the retentate were loaded on a 
pre-equilibrated Superdex 30 Prep Grade size exclusion with 20 mM Tris–HCl 
con- taining 0.15 M NaCl, pH 7.5, connected to an AKTA primePlus 
chromatographic system (GE Healthcare Life Sciences, Piscataway, NJ, USA) and 
lunasin was eluted with 20 mM Tris–HCl containing 0.15 M NaCl, pH 7.5, at a flow 
rate of 1 mL/min. Fractions were collected every 2 min and a total of 30 fractions 
were collected after one void volume. Lunasin was measured and confirmed by 
ELISA, SDS–PAGE and Western blot procedures.  
Circular dichroism (CD) 
Lunasin at a concentration of 0.075 mg/mL in PBS (pH 7.5) was heated at 
25, 37, 63, 72, 90 and 100 °C in succession, and the solution was maintained for 3 
min at specified temperature. CD spectra were recorded from 190 to 260 nm in a 1 
mm circular quartz cell at a scan rate of 100 nm/s with a 1-nm wavelength step 
and with 5 accumulations using the JASCO-720 spectropolarimeter (JASCO, 
Welltech Enterprises, Inc., Tokyo, Japan). Raw data files were analysed onto the 
DICHROWEB online server (http://dichroweb.cryst.bbk.ac.uk/html/process.shtml) 
using CDSSTR algorithm with reference set 4, which was optimized for the 
analysis of data recorded in the range from 190 to 240 nm (Lobley, Whitmore, & 
Wallace, 2002; Sreerama & Woody, 2000; Whitmore & Wallace, 2004).  
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Titer and specific activity determination of lunasin rabbit polyclonal 
antibody 
Lunasin purified from defatted soybean flour was dissolved in Tris buffered 
saline (TBS) at 5 μg/mL. One hundred microlitres of lunasin solution was plated in 
a 96-well plate and incubated over- night at 4 °C. After incubation, the plate was 
washed with phosphate buffered saline containing Tween 20 (PBS-T) using a 
BioTek plate washer (Winooski, VT, USA). The plate was blocked with 5% BSA in 
TBS containing 1% Tween 20 (TBST-1%) for 1 h at room temperature (RT) and 
washed again. One hundred microlitres of a 1:5 dilution of lunasin rabbit primary 
polyclonal antibody was added in the first row of the 96-well plate and a serial 2-
fold dilution of this antibody concentration was made in the succeeding wells 
plated with 50 μL of 3% BSA in TBST-1%. Fifty microlitres of anti-rabbit secondary 
antibody conjugated with alkaline phosphatase (1:1000) was added to each well 
and incubated for 1 h at RT. After washing, the colour was developed using p-
nitrophenyl phosphate (PNPP) substrate. The absorbance was read at 405 nm 
using ELX BioTek plate reader. A plot of absorbance versus the logarithm of the 
dilution factor was prepared and the dilution that resulted in half-maximum binding 
was reported as the lunasin rabbit primary polyclonal antibody titer. Specific 
activity of the antibody was calculated by dividing the titer to the protein 
concentration of the antibody and reported as mL/μg. 
Soluble protein determination 
Total soluble protein concentration was quantified using Bio-Rad Protein 
DC assay following manufacturer’s instructions. Briefly, 5 μL of sample was plated 
in a clear 96-well plate, 25 μLof Reagent A was added and 200 μLof Reagent B 
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thereafter. The colour was allowed to develop for 15 min at RT and the 
absorbance was measured at 630 nm using ELX Bio-Tek plate reader (Winooski, 
VT, USA). Protein concentration was calculated using bovine serum albumin 
(BSA) standard curve.  
Optimization of ELISA procedure to quantify lunasin 
One hundred microlitres of 8–100 ng/mL lunasin solution was plated in a 
96-well plate and incubated overnight at 4 °C. After washing, plate was blocked 
with 5% BSA in TBST-1% for 1 h at RT. After blocking and washing, 50 μL of the 
different dilutions of lunasin primary rabbit polyclonal antibody (1:200, 1:500, 
1:1000, 1:2000) was added and the plate was incubated for 1 h at RT. After 
washing, 50 μL of the 1:1000 dilution of anti-rabbit polyclonal secondary antibody 
was added and incubated for 1 h at RT. After washing, the colour was developed 
with colour reagent PNPP and the absorbance was read at 405 nm using ELX Bio-
Tek plate reader (Winooski, VT, USA). The reaction was stopped by adding 100 
μL of 3 N NaOH at 25 min and read again at 35 min. Lunasin concentration was 
quantified using a standard curve from different concentrations of purified lunasin. 
Primary antibody was diluted with 3% BSA, 1% Tween 20 and 0.05 M TBS buffer. 
All washings were done with 300 μL of washing solution, 6 times per well at the 
lowest dispensing rate (150 μL/well/s) and aspiration rate (5 mm/s) to avoid protein 
detachment.  
Blood sample collection and preparation 
The research protocol was approved by the Institutional Review Board of 
the University of Illinois at Urbana-Champaign. Healthy Caucasian males aged 
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18–25 y/o were recruited for the study. Exclusion criteria included smoking, 
vegetarianism and taking dietary supplements. Prior to blood collection, 
participants were asked to avoid consumption of soy products for one week. After 
one week of not consuming soy products, blood samples were collected from all 
participants. Blood samples were transported from the University clinic to the 
laboratory in a leak-proof container. Blood was centrifuged at 3000g for 15 min at 
4 °C to separate plasma from other blood cells. Plasma samples were stored at 
−80 °C until further analysis.  
Method for eluting and quantifying lunasin in human plasma 
DEAE resin was successively washed with deionized water until the 20% 
ethanol storage solution was removed. DEAE resin was resuspended in water in 
1:1 (v/v) ratio. Six hundred microlitres of the resuspended DEAE resin was 
pipetted out using a cut (45° angle) 1000-μL blue tip and added to a microspin 
column. The water was eluted by centrifugation at 1000 rpm for 30 s. Prepared 
human plasma was spiked with different amounts of lunasin ranging from 10 ng to 
2 μL.After spiking, human plasma-lunasin mixture was added to the packed DEAE 
resin and lunasin was allowed to bind to the resin for 2–3 h at RT by rotating the 
microspin column in an end-over-end rotator. After binding, unbound fraction was 
eluted and collected by centrifugation at 1000 rpm for 30 s. The elution profile of 
lunasin spiked in human plasma was studied by eluting lunasin using 20 mM Tris–
HCl buffer pH 7.5 with different concentrations of NaCl from 0 to 2 M. One 
hundred microlitres of eluate was plated in duplicate in a 96-well plate for 
quantifying lunasin using ELISA as described above. The total soluble protein 
concentration of each eluate was also quantified using the Bio-Rad Protein DC 
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assay as described above. Lunasin and protein elution profiles were plotted versus 
NaCl concentration. A plasma sample with no-spiked lunasin was also included to 
identify potential non-specific binding proteins. Yield for lunasin elution was 
calculated by taking the summation of all lunasin concentrations from each eluate 
and dividing the sum to the amount of lunasin used for spiking.  
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and 
Western Blot 
Eluate from human plasma spiked with 10 μg lunasin was mixed with 
Laemmli buffer containing β-mercaptoethanol and boiled for 5 min. Samples were 
loaded in a 4–20% Tris–HCl gel (Bio-Rad, Hercules CA) and proteins were 
separated at 200 V for 30 min. After electrophoresis separation, one gel was fixed 
with fixing buffer (acetic acid:methanol:water, 10:40:50 v/v/v) for 15 min, stained 
with Coomassie Brilliant Blue overnight and destained with 10% acetic acid for 20 
min. After destaining, gel was placed in deionized water and image was 
photographed using Kodak CF440 Imager (New Haven, CT). Another gel was 
equilibrated in blotting buffer (20% methanol in SDS–PAGE running buffer) for 15 
min at RT and proteins were transblotted in PVDF membrane at 110 V for 60 min 
in the cold room. After transblotting, membrane was blocked with 5% nonfat dry 
milk (NFDM) for 1 h at 4 °Cand washed with TBS containing 0.1% Tween 20 
(TBST-0.1%) 3 times 5 min each. After washing, membrane was incubated with 
lunasin primary rabbit polyclonal antibody (1:1000 in 1% NFDM) overnight at 4 
°C.After primary antibody incubation and repeated washings with TBST-0.1%, 
membrane was incubated with anti-rabbit secondary antibody conjugated with 
horseradish peroxidase (1:1000 in 1% NFDM) for 2–3 h at RT. After washing, the 
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membrane was imaged using a chemiluminiscence reagent (GE Healthcare Life 
Sciences) and Kodak CF440 Imager (New Haven, CT, USA).  
Statistical analysis 
All experiments were done in at least two independent replicates. Data are 
reported as mean ± standard deviation. Data were analyzed using SAS software 
version 9.2 and means separated by Tukey grouping at P < 0.05.  
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RESULTS AND DISCUSSION 
Purification of lunasin 
We report here a simple method of purification of lunasin from defatted 
soybean flour. Fig. 1A presents lunasin and protein concentrations of different 
fractions obtained from Superdex 30 Prep Grade gel filtration chromatography 
collected after one void volume. Earlier fractions showed that lunasin co-eluted 
with other high molecular mass proteins as evidenced by high lunasin 
concentration in these fractions, as determined by ELISA. In addition, a 
considerable amount of lunasin is observed in fractions 7, 8 and 9. Western blot 
profile showed that lunasin is present in these fractions (Fig. 1B). Moreover, SDS–
PAGE Coomassie staining of these fractions showed high purity of lunasin 
preparation. Fig. 1C shows the electrophoresis profiles of different fractions during 
lunasin purification. As can be seen from the SDS–PAGE Coomassie staining, a 
purified lunasin extract was prepared after a successive DEAE ion-exchange 
chromatography (lanes 1 and 4), Superdex 75 gel filtration chromatography (lanes 
2 and 5) and Superdex 30 gel filtration chromatography (lanes 3 and 6). This is 
further confirmed by the immunoreactivity of the 5 kDa band against the lunasin 
rabbit polyclonal antibody corresponding to lanes 4, 5 and 6. This purification 
method presented several advantages as the previously described method of 
lunasin preparation (Cavazos, Morales, Dia, & Gonzalez de Mejia, 2012; de Mejia 
& Dia, 2009; Dia et al., 2009a) including high purity of lunasin preparation and high 
reproducibility which might be attributed to the use of an automated gel filtration 
chromatographic systems. In addition, less cost was involved as ultracentrifugation 
filters (Cavazos et al., 2012) were not used.  
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Fig. 1. Lunasin and protein concentrations of Superdex 30 Prep Grade gel filtration fractions 
collected after one void volume (A), Coomassie staining and Western blot profiles of Superdex 30 
Prepgrade gel filtration fractions containing high concentrations of lunasin as previously measured 
by ELISA (B) and Coomassie staining and Western blot profiles of lunasin extract from different 
stages of purification (C). MW: molecular mass standard; lanes 1 and 4: desalted ion-exchange 
fraction containing high concentration of lunasin from two independent preparations; lanes 2 and 5: 
desalted gel filtration fraction from Superdex 75 gel filtration chromatography containing high 
concentration of lunasin from two independent preparations; lanes 3 and 6: desalted and purified 
lunasin from gel filtration fraction using Superdex 30 from two independent preparations; lanes 7, 8 
and 9 represent the Western blot profiles of lanes 4, 5 and 6, respectively.  
 
Structural property of lunasin as measured by CD 
Fig. 2 presents the data deconvolution of the ellipticity of lunasin solution at 
25 °Cusing CDSSTR algorithm; lunasin has 29% α-helix, 28% β-strands,23% 
turns and 20% unordered. The effect of temperature on the structural changes of 
lunasin was monitored from the appearance of a minimum peak at 205 nm and a 
weak shoulder at 222 nm as shown in Fig. 2A. No significant change from the CD 
spectra at 222 nm was observed until reaching 72 °Cwhile a significant change 
was observed starting at 90 °Cwhich reflected the α-helixstructure of the folded 
protein. Consistent with this change, the increase in the minimum peak observed 
at 205 nm when the temperature was increased from 25 to 100 °Cindicated 
increased randomness in the structure. Plotting ellipticity versus heating 
temperature, allows the determination of the thermal unfolding and denaturation of 
lunasin (Fig. 2B); lunasin unfolding did not start until 90 °C.The capability of the 
heated lunasin solution to interact with the rabbit polyclonal antibody produced 
against lunasin epitope was also determined. There was a 24.4% reduction in the 
affinity towards the antibody of the heated lunasin (100 °C)when compared to the 
unheated lunasin solution as evidenced by a reduction of slope of the standard 
curve prepared from heated lunasin solution (y = 0.019 x − 0.039, R2 = 0.99) and 
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unheated lunasin solution (y = 0.025 x + 0.176, R2 = 0.98). This observation is the 
first to report the effect of heating on the capability of lunasin to interact with the 
rabbit polyclonal antibody. Lunasin concentrations in heated soy products such as 
soymilk and tofu have been reported in previous publications (Cavazos et al., 
2012; Gonzalez de Mejia, Vasconez, de Lumen, & Nelson, 2004; Hernandez-
Ledesma et al., 2009a, 2009b). The reduction in the affinity of heated lunasin with 
the antibody can be explained by the changes in the structural features of the 
lunasin molecule as supported by the CD (inserted table in Fig. 2A).  
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Fig. 2.Circular dichroism spectra of lunasin as affected by different heating temperatures. The 
secondary structure of lunasin was calculated using the DICHROWEB tool using CDSSTR 
algorithm (A). Thermal unfolding of lunasin as monitored by CD at 222 nm (B). Protein 
concentration was 0.075 mg/mL. CD values are presented in ellipticity, mdeg, obtained from 190 to 
260 nm in a 1 mm circular quartz cell at a scan rate of 100 nm/s with a 1-nm wavelength step and 
with 5 accumulations using a JASCO-720 spectropolarimeter. The inserted table presents the 
percentage of each component of the secondary structure conformation obtained from the CD 
spectra at 25 and 90 °C. 
 
Characteristic of the lunasin rabbit primary polyclonal antibody and 
optimization of antibody concentrations for ELISA 
Determination of the titer of an antibody is a common method of 
characterising an antibody for an immunoassay protocol in order to identify the 
optimum dilution or concentration of antibody that will give the best antigen–
antibody interaction with minimum background and non-specific binding. Fig. 3A 
shows the effect of antibody dilution on the capability of lunasin to interact with the 
antibody resulting in the determination of antibody titer. As shown in Fig. 3A, 
maximum binding occurred at 1:40 antibody dilution with an average absorbance 
at 405 nm of 3.8 while minimum response was seen at the lowest dilution of 
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1:5120 with an absorbance of 0.10. The titer for the antibody, defined as the 
dilution that resulted in half-maximum binding, was 1.9 absorbance units; the 
logarithm of the dilution factor was 2.4 which corresponded to a titer (dilution of the 
antibody) of 250. This means that at a dilution of 1:250, lunasin rabbit polyclonal 
antibody will give the best antibody-antigen interaction with minimal background 
and nonspecific binding. The specific activity of the antibody, obtained by dividing 
the titer (250) to the protein concentration (5187.5 μg/mL) of the antibody, was 
0.05 mL/μg. 
To further optimize the ELISA procedure for measuring lunasin 
concentration, independent experiments using different dilutions of the primary 
antibody and testing different concentrations of lunasin were performed. Fig. 3B 
shows the response of different primary antibody dilutions to different 
concentrations of lunasin. A linear response to lunasin concentrations was 
observed at primary antibody dilution of 1:200 and 1:500. It was decided to use the 
1:200 antibody dilution as this dilution was closer to the antibody titer found initially 
in this study and the response was similar to our previously reported study using 
mouse monoclonal antibody (Dia, Torres, de Lumen, Erdman, & de Mejia, 2009b). 
It was also found that at this combination of antibody dilution (1:200 for lunasin 
primary rabbit polyclonal antibody and 1:1000 for the anti-rabbit secondary 
antibody), the assay had a linear range between 16 and 48 ng lunasin/mL with a 
R2 of 0.96 (Fig. 3C). When the highest concentration was 44ng lunasin/mL, the 
linearity was improved (y = 0.028x − 0.298, R2of 0.98). This is the first report on 
the characteristics of lunasin primary rabbit polyclonal antibody. The linear range 
obtained in the present study is almost similar to previously reported method using 
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mouse monoclonal antibody (Gonzalez de Mejia et al., 2004) of 24–72 ng 
lunasin/mL with very similar R2 of 0.96 (Fig. 3C).  
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Fig. 3.Determination of titer for lunasin primary rabbit polyclonal antibody. One hundred microlitres 
of 5 μg/mL lunasin solution was plated in a 96-well plate and incubated overnight at 4 °C,the 
secondary anti-rabbit antibody conjugated with alkaline phosphatase was diluted 1000� with 3% 
BSA in 1% TBST (A). Effect of primary lunasin antibody dilutions and lunasin concentration on the 
determination of lunasin in plasma by ELISA. Constant anti-rabbit secondary antibody conjugated 
with alkaline phosphatase (1:1000) with varying primary lunasin antibody dilutions (B). Standard 
curve for lunasin using 1:200 and 1:1000 dilutions for primary and secondary antibodies, 
respectively showing linear range from 16 to 48 ng lunasin/mL (C).  
 
Diethylaminoethyl (DEAE) microspin anion exchange column as a 
method for quantifying lunasin in plasma 
An important characteristic of any bioactive compound is its ability to resist 
gastrointestinal digestion and be absorbed to the circulation thereby can reach 
target tissues and organs in order to exert its biological activity. We report here a 
simple method of quantifying lunasin in human plasma. Fig. 4A presents the 
lunasin profile of different eluates from the DEAE microspin column eluted with 
different concentrations of NaCl in Tris–HCl buffer, pH 7.5. A small percentage of 
lunasin was not able to bind to the resin as measured by lunasin concentration in 
the unbound eluate. The amount of lunasin in the unbound eluate corresponds to 
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5.1– 8.2% of the total amount of lunasin eluted from the DEAE microspin resin. On 
the other hand, most lunasin eluted from the DEAE microspin column at the Tris–
HCl buffer with no NaCl added. The amount of lunasin from this eluate ranged 
from 28.6% (plasma spiked with 100 ng lunasin) to 46.5% (plasma spiked with 2 
μglunasin) of the total amount of lunasin eluted. The amount of spiked lunasin 
correlated well to the amount of lunasin eluted by Tris–HCl buffer (R2 = 0.82).The 
remainder of the lunasin was then eluted with Tris–HCl buffer containing different 
concentrations of NaCl from 0.1 to 2 M. The result showed that the spiked lunasin 
had a weak binding to the DEAE resin used as it eluted from the resin at a buffer 
with no need of NaCl. At a pH of 7.5, we expected that most lunasin will be bound 
to the resin as it will have a strong net negative charge attributed to its nine 
aspartic acid residues on its carboxylic acid end. Our previous study on the 
isolation of lunasin from defatted soybean flour showed that most lunasin eluted 
from the DEAE resin at 0.4 M NaCl (Dia et al., 2009b). Moreover, isolation of 
lunasin from plasma of men fed with 50 g soy protein showed that lunasin from 
human plasma eluted at 0.15–0.20 M NaCl (Dia et al., 2009a). The differences 
were on the pH of the buffer used (20 mM Triethanolamine, pH 8.0 vs 20 mM Tris–
HCl, pH 7.5), the resin used to bind lunasin (strong anionic magnetic beads vs. 
DEAE), as well as the effect of the human plasma protein matrix on the binding 
capability of the spiked lunasin. In comparing the elution profile of spiked lunasin 
from lunasin in defatted soybean flour, both procedures used a DEAE resin; 
however, the spiked lunasin in plasma eluted without the need of NaCl in contrast 
to the 0.4 M NaCl needed to elute lunasin from defatted soybean flour. This can be 
explained by the effect of other proteins present in the human plasma, the matrix, 
which affected the binding affinity of lunasin to DEAE resin. The yield of lunasin 
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from the DEAE microspin column ranged from 50.7 to 76.6% (Table 1) indicating 
that there is still a considerable amount of lunasin that was retained in the DEAE 
microspin column that might be eluted with extended washes of Tris–HCl buffer 
with higher NaCl concentration. On the other hand, the protein concentrations of 
each eluate from plasma spiked with different concentrations of lunasin vary 
slightly with each other (Fig. 4B).  
 
 
 
 
 
 
 
Table 1 
Yield of lunasin from the DEAE* microspin column. 
Amount of lunasin spiked to plasma, μg Yield, %** 
2.0 50.7 ± 2.3
b 
1.0 76.6 ± 6.1
a 
0.5 56.2 ± 3.1
b 
0.1 68.6 ± 8.5
a 
0.05 ND*** 
0.01 ND 
* Diethylaminoethyl anion exchange resin 
** Calculated based on the cumulative amount of lunasin eluted from the DEAE microspin column 
and divided by the amount of lunasin spiked to plasma. Means followed by different letter are 
significantly different from each other, P < 0.05. 
*** ND – not determined 
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Fig. 4. Lunasin (A) and protein (B) concentrations of eluates from DEAE microspin column derived 
from human plasma spiked with different amounts of lunasin. Lunasin was eluted from the plasma 
using 20 mM Tris–HCl buffer pH 7.5 with different NaCl concentrations. PBS-spiked plasma 
showed no presence of detectable lunasin in the eluates from different concentrations of NaCl 
used for elution. Means within the same eluate followed by different letters are statistically different 
from each other (P < 0.05).  
 
To further validate the elution profile of lunasin from plasma, the plasma 
sample was spiked with 10 μglunasin and eluted with buffer pH 7.5 and different 
concentrations of NaCl ranging from 0 to 1 M. The protein profile of the eluate was 
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determined by SDS– PAGE and the identity of lunasin was confirmed by Western 
blot. Fig. 5 shows the SDS–PAGE profile and the Western blot for these eluates. 
As can be seen from the gel, the protein profile of the eluate differs from each 
other based on the NaCl concentration present in the buffer which can be 
explained by the different proteins present in human plasma. The identity of 
lunasin eluted from the plasma was further confirmed by a strong 
chemiluminiscence at 5 kDa band, molecular mass of lunasin based on its 
reported amino acid composition.  
 
Fig. 5. SDS–PAGE (A) and Western blot (B) profiles of different eluates from DEAE microspin 
column derived from human plasma spiked with 10 μglunasin. MW: molecular mass standard, A: 
unbound eluate, B: Tris–HCl eluate, C: Tris–HCl with 0.1 M NaCl eluate, D: Tris–HCl with 0.4 M 
NaCl eluate, E: Tris–HCl with 1 M NaCl eluate.  
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Previous studies have shown the bioavailability of lunasin in human as well 
as in animals. For instance, the bioavailability study in humans used an expensive 
commercially available strong anionic bead to capture lunasin by means of 
magnetic property of the beads from the plasma and eluted it with buffer with 
different salt concentrations (Dia et al., 2009b). Bioavailability study in animals 
used laborious and time-consuming purification protocol to detect and measure 
lunasin. The study of Hsieh et al. (2010a) used an isotope-labelled 3H-lunasin and 
the concentration of lunasin from different tissues and organs were determined by 
scintillation counting. Other studies conducted a combination of ion-exchange 
chromatography and HPLC in order to purify lunasin in freeze dried organs 
showing bioavailability of lunasin (Jeong, Jeong, Kim et al., 2007, Jeong, Jeong, 
Park et al., 2007; Jeong et al., 2009). The method presented in this study has 
several advantages such as shorter procedure time, no use of sophisticated 
equipment or reagents, and less expensive. One disadvantage though is the 
incomplete elution of the spiked lunasin which can be resolved by adding more 
wash elution steps with buffer containing concentration of NaCl higher than 2 M.  
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CONCLUSIONS 
For the first time the structural property of lunasin and the effect of 
temperature on its structure and capability to interact with rabbit polyclonal 
antibody was demonstrated. In addition, different characteristics of lunasin primary 
rabbit polyclonal antibody for quantifying lunasin in human plasma using an 
optimized ELISA protocol are reported. Lunasin from human plasma can be 
isolated by a simple DEAE microspin column technique and can be quantified 
using a validated and optimized immunoassay procedure.  
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